VedaBio vs Vinci
Side-by-side comparison of AI visibility scores, market position, and capabilities
Precision genome editing biotech developing base and prime editors for rare genetic diseases; improved specificity over first-generation CRISPR competing with Beam Therapeutics and Intellia.
About
Veda Bio is a biotechnology company developing novel therapeutics for rare genetic diseases and cancer using its proprietary precision genome editing platform — enabling targeted genetic corrections with greater specificity and reduced off-target editing compared to first-generation CRISPR tools. Founded in 2019 and headquartered in Seattle, Washington, Veda Bio was founded by genome editing pioneers and has raised early-stage funding to develop its differentiated editing technology platform.\n\nVeda Bio's platform focuses on delivering precision genetic medicine that can address root causes of genetic diseases rather than managing symptoms. The company's approach aims to improve on first-generation CRISPR-Cas9 by developing base editors and prime editors that can make specific genetic corrections (single letter DNA changes, small insertions or deletions) without introducing double-strand DNA breaks that create higher off-target editing risk. This precision is critical for therapeutic applications where off-target genomic changes could have serious safety consequences.\n\nIn 2025, Veda Bio operates in the competitive genome editing therapeutics space alongside Intellia Therapeutics, Beam Therapeutics (base editing pioneer), Prime Medicine, and CRISPR Therapeutics. The genome editing field experienced a landmark moment in 2023 with the FDA approval of Casgevy (the first CRISPR-based therapy, for sickle cell disease and beta-thalassemia, developed by Vertex and CRISPR Therapeutics) — validating the genome editing therapeutic modality and creating competitive pressure for improved precision editing platforms. Veda Bio's 2025 strategy focuses on advancing lead programs in rare genetic indications through preclinical development toward IND applications, publishing research to establish scientific credibility, and exploring partnerships or licensing with larger biopharmaceuticals for clinical development.
Nanterre global concessions and construction (EPA: DG, CAC 40) at €71.6B 2024 revenue record and €4.9B net income; 72 airports/4,400km toll roads with Edinburgh Airport acquisition competing with ACS for global infrastructure concessions.
About
VINCI SA is a Nanterre, France-headquartered global concessions and construction group — listed on Euronext Paris (EPA: DG) as a CAC 40 component — reporting record €71.6 billion in revenue and €4.9 billion in net income for 2024, employing 285,000 people across 120+ countries in three business divisions: Vinci Concessions (€11.7 billion revenue, operating 4,400 km of toll roads and 72 airports including Gatwick and Edinburgh airports in 14 countries), Vinci Energies (€27.5 billion revenue, energy transition and digital infrastructure services), and Vinci Construction (€31.8 billion revenue, civil engineering, buildings, and hydraulic engineering). International markets represent 58% of total revenue. CEO Xavier Huillard has led VINCI since 2010; Pierre Anjolras serves as incoming COO. Key acquisitions include ANA Aeroportos de Portugal (€3.08B, 2012), Gatwick Airport 50.01% (2019), ACS Industrial Services division (€5.2B, 2021), and Edinburgh Airport 50.01% (2024). Founded 1899 as Société Générale d'Entreprises.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.